Cargando…
Outcomes of a 2-year treat-and-extend regimen with aflibercept for diabetic macular edema
This prospective, open-label, single-arm, non-randomized clinical trial, assessed the efficacy of a 2-year treat-and-extend (T&E) regimen involving intravitreal aflibercept injection (IAI), with the longest treatment interval set to 16 weeks, and adjunct focal/grid laser in diabetic macula edema...
Autores principales: | Hirano, Takao, Toriyama, Yuichi, Takamura, Yoshihiro, Sugimoto, Masahiko, Nagaoka, Taiji, Sugiura, Yoshimi, Okamoto, Fumiki, Saito, Michiyuki, Noda, Kousuke, Yoshida, Shigeo, Ishibazawa, Akihiro, Sawada, Osamu, Murata, Toshinori |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7904904/ https://www.ncbi.nlm.nih.gov/pubmed/33627712 http://dx.doi.org/10.1038/s41598-021-83811-y |
Ejemplares similares
-
CHANGES IN PLASMA VASCULAR ENDOTHELIAL GROWTH FACTOR LEVEL AFTER INTRAVITREAL INJECTION OF BEVACIZUMAB, AFLIBERCEPT, OR RANIBIZUMAB FOR DIABETIC MACULAR EDEMA
por: Hirano, Takao, et al.
Publicado: (2018) -
Changes in metamorphopsia following intravitreal aflibercept injection for diabetic macular edema
por: Murakami, Tomoya, et al.
Publicado: (2022) -
The Impact of Interval between Recurrence and Reinjection in Anti-VEGF Therapy for Diabetic Macular Edema in Pro Re Nata Regimen
por: Takamura, Yoshihiro, et al.
Publicado: (2021) -
Retinal arterial occlusive vasculitis after multiple intravitreal brolucizumab injections for diabetic macular edema
por: Hirano, Takao, et al.
Publicado: (2022) -
Short-term effects of intravitreal ranibizumab therapy on diabetic macular edema
por: Minami, Yoshiro, et al.
Publicado: (2017)